Author:
At Thobari Jarir,Krisdinarti Lucia,Nugroho Dhite,Haposan Jonathan,Firdaus Isman,Suryandani Rr. Arum Ramadhyan,Munawar Muhammad,Agung Jimmy
Abstract
Background: Acute coronary syndromes (ACS) are life-threatening CVD associated with Indonesia's significant health and economic burdens. The study objective was to evaluate the cost-effectiveness of ticagrelor in reducing CV endpoint in the Indonesia setting.
Methods: Markov model was used as a decision analysis to compare ticagrelor with clopidogrel. We constructed decision tree model included four health conditions (no additional events, non-fatal myocardial infarction, non-fatal stroke, and any cause death), The probability of each state and quality-adjusted life years were derived from the PLATO trial and Indonesia life table. The outcome's resource consumption and associated costs were collected from three hospitals (public, national referral, and private hospitals) in Indonesia. The study used 5 years and lifetime horizon and discounting rate of 3%.
Results: The incremental QALYs and life-year gained (LYG) of ticagrelor in five years was 0.0410 and 0.0462, respectively; in a lifetime was 0.0828, and 0.0947, respectively. The ICER per QALY of ticagrelor versus clopidogrel in private, national referral, and public hospitals was USD 2390.276, USD 3813.638, USD 1278.361, respectively for five years; and USD 2471.392, USD 5453.987, USD 2343.269, respectively for a lifetime. The probability of ticagrelor to be cost-effective was about 66.6% on a five-year and 99.7% on a lifetime with WTP USD 3634.
Conclusion: Compared to the clopidogrel, QALYs and life-year gained of use ticagrelor higher. The incremental cost-effectiveness ratio in five years and lifetime model showed under one-time GDP, it means the use of ticagrelor was vastly cost-effective and acceptable to apply in the Indonesian clinical setting.
Publisher
Scientific Foundation SPIROSKI
Reference24 articles.
1. Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Med Sci Monit. 2009;15(12):Ms24-30. PMid:19946242
2. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation. 2009;120(25):2577-85. https://doi.org/10.1161/circulationaha.109.912550 PMid:19923168
3. Henriksson M, Nikolic E, Ohna A, Wallentin L, Janzon M. Ticagrelor treatment in acute coronary syndrome is cost-effective in Sweden and Denmark. Scand Cardiovasc J. 2014;48(3):138-47. https://doi.org/10.3109/14017431.2014.902494 PMid:24650118
4. Henriksson M, Janzon M. Cost-effectiveness of ticagrelor in acute coronary syndromes. J Expert Rev Pharmacoeconomics Outcomes Res. 2013;13(1):9-18. https://doi.org/10.1586/erp.12.89
5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. J N Engl J Med. 2009;361(11):1045-57. https://doi.org/10.1056/nejmoa0904327 PMid:19717846
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献